Leerink Partnrs Predicts Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN) – Stock analysts at Leerink Partnrs issued their Q2 2026 earnings per share (EPS) estimates for Myriad Genetics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0.02) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

Several other research firms have also recently commented on MYGN. Piper Sandler cut their price target on Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, January 30th. UBS Group cut their price objective on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday. Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $30.00 to $21.00 in a research note on Monday, December 9th. The Goldman Sachs Group cut their price objective on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Stephens restated an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research note on Thursday, January 16th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.14.

Myriad Genetics Trading Down 1.5 %

NASDAQ:MYGN opened at $11.56 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics has a one year low of $9.76 and a one year high of $29.30. The business’s 50-day simple moving average is $13.37 and its 200 day simple moving average is $19.21. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -8.89 and a beta of 1.88.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. During the same quarter last year, the firm posted ($0.12) EPS.

Hedge Funds Weigh In On Myriad Genetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MYGN. Point72 Hong Kong Ltd bought a new position in Myriad Genetics in the 3rd quarter worth approximately $32,000. Sterling Capital Management LLC grew its holdings in Myriad Genetics by 829.9% in the 4th quarter. Sterling Capital Management LLC now owns 2,864 shares of the company’s stock worth $39,000 after buying an additional 2,556 shares in the last quarter. KBC Group NV boosted its stake in Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock valued at $80,000 after purchasing an additional 3,334 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Myriad Genetics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after purchasing an additional 583 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in Myriad Genetics by 43.8% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.